Need Immediate Care?

Find Urgent Care Locations

A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis (ZAPPHIRE)

Short Title: Zapphire

Enrollment Status: Recruiting

NCT #: NCT07516951

Specialty Area: Pulmonology

Condition Studied: Idiopathic Pulmonary Fibrosis (IPF)

Age Groups: Adult; Older Adult

Phase: II

Study Information

Summary / Purpose

To evaluate the efficacy of 2 dose strengths of CHF10067 in terms of change from baseline in percent predicted forced vital capacity (ppFVC) at Week 24 compared to placebo in the entire study population.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 40+ years of age
Diagnosed with idiopathic pulmonary fibrosis (IPF) within the past 8 years
Have been receiving stable IPF treatment plan for at least 4 weeks
Have a DLCO, a measure of how well oxygen passes from the lungs into the blood, of at least 25% of the predicted value
Have an oxygen level above 90% at rest, with or without supplemental oxygen up to the study’s allowed limit

What's Involved

Participation in the study will include:

Study drug administration via infusion
High resolution CT (HRCT)
Electrocardiogram (ECG)
Breathing tests (Pulmonary Function Testing [PFT]), including spirometry and diffusing capacity of the lung for carbon monoxide (DLCO)
Questionaires
Blood and urine tests

Principal Investigator

Farah Madhani-Lovely, MD

Pulmonology

A Member of

(775) 982–5000

Renown Medical Group – Pulmonary Medicine

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT07516951

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews